77 related articles for article (PubMed ID: 3690546)
21. An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
Asbury RF; Cnaan A; Johnson L; Harris J; Zaentz SD; Haller DG
Am J Clin Oncol; 1994 Apr; 17(2):166-9. PubMed ID: 8141110
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of spirogermanium in advanced breast cancer.
Kuebler JP; Tormey DC; Harper GR; Chang YC; Khandekar JD; Falkson G
Cancer Treat Rep; 1984 Dec; 68(12):1515-6. PubMed ID: 6509457
[No Abstract] [Full Text] [Related]
23. Phase I study of oral spirogermanium.
Harvey J; McFadden M; Smith FP; Joubert L; Schein PS
Invest New Drugs; 1990 Feb; 8(1):53-6. PubMed ID: 2345069
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of spirogermanium in patients with advanced colorectal carcinoma.
Ajani JA; Faintuch JS; McClure RK; Levin B; Boman BM; Krakoff IH
Invest New Drugs; 1986; 4(4):383-5. PubMed ID: 3583645
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study.
Lad TE; Blough RR; Evrard M; Shevrin DP; Cobleigh MA; Johnson CM; Hange P
Invest New Drugs; 1989 Jul; 7(2-3):223-4. PubMed ID: 2551841
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
Ettinger DS; Finkelstein DM; Donehower RC; Chang AY; Green M; Blum R; Hahn RG; Ruckdeschel JC
Med Pediatr Oncol; 1989; 17(3):197-201. PubMed ID: 2546026
[TBL] [Abstract][Full Text] [Related]
27. Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.
Novik Y; Ryan LM; Haller DG; Asbury R; Dutcher JP; Schutt A
Med Oncol; 1999 Dec; 16(4):261-6. PubMed ID: 10618689
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of spirogermanium in patients with advanced malignant lymphoma.
Sessa C; ten Bokkel Huinik W; Clavel M; Lev LM; Joss RA; Renard J; Cavalli F
Invest New Drugs; 1989 Jul; 7(2-3):219-22. PubMed ID: 2793376
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of spirogermanium given by infusion in a multiple-dose schedule.
Budman DR; Schulman P; Vinciguerra V; Degnan TJ
Cancer Treat Rep; 1982 Jan; 66(1):173-5. PubMed ID: 7053254
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of spirogermanium in advanced human malignancy.
Vogelzang NJ; Gesme DH; Kennedy BJ
Am J Clin Oncol; 1985 Aug; 8(4):341-4. PubMed ID: 3909806
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary toxicity associated with spirogermanium.
Dixon C; Hagemeister F; Legha S; Bodey G
Cancer Treat Rep; 1984 Jun; 68(6):907-8. PubMed ID: 6733705
[No Abstract] [Full Text] [Related]
32. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.
Eisenhauer E; Quirt I; Connors JM; Maroun J; Skillings J
Invest New Drugs; 1985; 3(3):307-10. PubMed ID: 4066225
[TBL] [Abstract][Full Text] [Related]
33. Phase I clinical trial of spirogermanium.
Schein PS; Slavik M; Smythe T; Hoth D; Smith F; Macdonald JS; Woolley PV
Cancer Treat Rep; 1980; 64(10-11):1051-6. PubMed ID: 7459890
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials Group Study.
Eisenhauer E; Kerr I; Bodurtha A; Iscoe N; McCulloch P; Pritchard K; Quirt I
Invest New Drugs; 1985; 3(3):303-5. PubMed ID: 4066224
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of dianhydrogalactitol in advanced renal cell carcinoma: a Southwest Oncology Group study.
Ratanatharathorn V; Baker LH; Balducci L; Talley RW; Hoogstraten B
Cancer Treat Rep; 1982 May; 66(5):1231-2. PubMed ID: 7083224
[No Abstract] [Full Text] [Related]
36. [Treatment of advanced carcinoma of the prostate with estramustine phosphate (estracyt)].
Lancina Martín JA; Chantada Abal V; Lamas Meilan AC; González Martín M
Actas Urol Esp; 1984; 8(5):399-402. PubMed ID: 6524487
[No Abstract] [Full Text] [Related]
37. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Osborne CK; Drelichman A; Von Hoff DD; Crawford ED
Cancer Treat Rep; 1983 Dec; 67(12):1133-5. PubMed ID: 6652630
[TBL] [Abstract][Full Text] [Related]
38. Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.
Slavik M; Blanc O; Davis J
Invest New Drugs; 1983; 1(3):225-34. PubMed ID: 6678870
[TBL] [Abstract][Full Text] [Related]
39. Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
Swanson GP; Faulkner J; Smalley SR; Noble MJ; Stephens RL; O'Rourke TJ; Weiss GR; Quick DP; Thompson IM; Crawford ED
J Urol; 2006 Aug; 176(2):548-53; discussion 553. PubMed ID: 16813886
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of health promotive effect of organometallic germanium compounds].
Wang YL
Zhonghua Yu Fang Yi Xue Za Zhi; 1994 Nov; 28(6):372-4. PubMed ID: 7867458
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
